Skip to main content

Advertisement

SpringerLink
Log in

Comparative epidemiology of hospital-acquired adverse drug reactions in adults and children and their impact on cost and hospital stay – a systematic review

  • Review Article
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

To study and analyze the comparative impact of hospital-acquired adverse drug reactions (ADRs) in adult and pediatric patients in terms of the economic implications, (length of) hospital stay, and salient features in relation to the incidence rate, severity, morbidity, mortality, and preventability of the ADRs.

Methods

A systematic search to identify and retrieve relevant articles/studies in the PubMed, Medline, Scopus, MEDPAR, and Cochrane databases and by the Google search engine was performed for the study period 2000 to April 2013. In total, 51 studies were identified on patients hospitalized for ADRs, and these were included in the study. The incidence rate of ADRs, their severity, mortality, morbidity, preventability, cost, and association with extended hospital stay due to ADRs were extracted and scrutinized.

Results

Hospital-acquired ADRs are more widely studied in adults than in children, and the incidence rate is higher in the former. However, a wide variation in the incidence rate worldwide is observed in both groups. Irrespective of the ages of patients, ADRs are among the most frequent causes of morbidity and mortality. Interestingly, preventable ADRs are more frequently observed in patients at the younger and older ends of the age spectrum. Hospital-acquired ADRs place an immense economic burden on healthcare systems, with the overall cost for a hospitalized patient with an ADR reported to be $2,401 per patient, which is equivalent to a 19.86 % additional increase in the total cost of care and an increase in average length of hospital stay of 8.25 %.

Conclusion

Based on the findings of this review, we suggest that excellent assertive measures of pharmacovigilance with the aim to diminish the incidence rate of hospital-acquired ADRs and support the development of interventions are needed to promote vital facets of drug safety with an overall objective to avert potential ADRs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. IMS (2011) The use of medicines in the United States: overview of 2010. IMS Institute for Healthcare Informatics, Danbury

  2. IMS (2011) The hlobal use of medicines: outlook through 2015. IMS Institute for Healthcare Informatics, Danbury

  3. Barach P, Small SD (2000) Reporting and preventing medical mishaps: lessons from non-medical near miss reporting systems. Br Med J 320:759–763

    Article  CAS  Google Scholar 

  4. Blake DR (2003) Alternative prescribing and negligence. Br Med J 326:455

    Article  Google Scholar 

  5. Wiffen P, Gill M, Edwards J, Moore A (2002) Adverse drug reactions in hospital patients. Bandolier Extra 1–15

  6. World Health Organization (WHO) (1972) WHO Technical Report 498. Available at: www.who.int/tdr

  7. Ritter M (2008) Minimizing harm: human variation and adverse drug reactions (ADRs). Br J Clin Pharmacol 65:451–452

    Article  PubMed  CAS  Google Scholar 

  8. Krizek TJ (2000) Surgical error: ethical issues of adverse events. Arch Surg 135:1359–1366

    Article  PubMed  CAS  Google Scholar 

  9. Thürmann PA (2001) Methods and systems to detect adverse drug reactions in hospitals. Drug Saf 24(13):961–968

    Article  PubMed  Google Scholar 

  10. Arulmani R, Rajendran SD, Suresh B (2008) Adverse drug reaction monitoring in a secondary care hospital in South India. Br J Clin Pharmacol 65:210–216

    Google Scholar 

  11. Ramesh M, Pandit J, Parthasarathi G (2003) Adverse drug reactions in a south Indian hospital—their severity and cost involved. Pharmacoepidemiol Drug Saf 12:687–692

    Article  PubMed  CAS  Google Scholar 

  12. Jose J, Rao PG (2006) Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital. Pharmacol Res 54:226–233

    Article  PubMed  Google Scholar 

  13. Le J, Nguyen T, Law AV, Hodding J (2006) Adverse drug reactions among children over a 10-year period. Pediatrics 118:555–562

    Article  PubMed  Google Scholar 

  14. Mehta U, Durrheim DN, Blockman M, Kredo T, Gounden R, Barnes KI (2008) Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence: prospective observational study. Br J Clin Pharmacol 65:396–406

    Article  PubMed  Google Scholar 

  15. Aagaard L, Christensen A, Hansen EH (2010) Information about adverse drug reactions reported in children: a qualitative review of empirical studies. Br J Clin Pharmacol 70:481–491

    Article  PubMed  Google Scholar 

  16. Easton L, Chapman C, Brien J (2004) Frequency and characteristics of hospital admissions associated with drug-related problems in paediatrics. Br J Clin Pharmacol 57(5):611–615

    Article  PubMed  Google Scholar 

  17. Eliasson E (2006) Ethnicity and adverse drug reactions. Br Med J 332:1163–1164

    Article  Google Scholar 

  18. Lopez AD, Mathers CD, Ezzati M et al (2006) Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367:1747–1757

    Google Scholar 

  19. Bond CA, Raehl CL (2006) Adverse drug reactions in United States hospitals. Pharmacotherapy 26(5):601–608

    Article  PubMed  CAS  Google Scholar 

  20. Vora MB, Trivedi HR, Shah BK et al (2011) Adverse drug reactions in inpatients of internal medicine wards at a tertiary care hospital: A prospective cohort study. J Pharmacol Pharmacother 2:21–25

    Google Scholar 

  21. Pourseyed S, Fattahi F, Pourpak Z et al (2009) Adverse drug reactions in patients in an Iranian department of internal medicine. Pharmacoepidemiol Drug Saf 18:104–110

    Google Scholar 

  22. Khan LM, Al-Harthi SE, Saadah OI et al (2012) “Impact of pharmacovigilance on adverse drug reactions reporting in hospitalized internal medicine patients at Saudi Arabian teaching hospital.”. Saudi Med J 33(8):863–868

    Google Scholar 

  23. Davies EC, Green CF, Mottram DR et al (2006) Adverse drug reactions in hospital in-patients: a pilot study. J Clin Pharm Ther 31:335–341

    Google Scholar 

  24. Davies EC, Green CF, Taylor S, Williamson PR et al (2009) Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One 4(2):e4439. doi:10.1371/journal.pone.0004439

  25. Suh D-C, Woodall BS, Shin S-K et al (2000). Clinical and economic impact of adverse drug reactions in hospitalized patients. Ann Pharmacother 34:1373–1379

    Google Scholar 

  26. Calderón-Ospina C, Bustamante-Rojas C (2010) The DoTS classification is a useful way to classify adverse drug reactions: a preliminary study in hospitalized patients. Int J Pharm Pract 18(4):230–235

    Article  PubMed  Google Scholar 

  27. Mohebbi N, Shalviri G, Salarifar M et al (2010) Adverse drug reactions induced by cardiovascular drugs in cardiovascular care unit patients. Pharmacoepidemiol Drug Saf 19(9):889–894

    Article  PubMed  Google Scholar 

  28. Harugeri A, Parthasarathi G, Ramesh M et al (2011) Frequency and nature of adverse drug reactions in elderly in-patients of two Indian medical college hospitals. J Post Grad Med 57(3):189–195

    Google Scholar 

  29. Doshi MS, Patel PP, Shah SP et al (2012) Intensive monitoring of adverse drug reactions in hospitalized patients of two medical units at a tertiary care teaching hospital. J Pharmacol Pharmacother 3(4):308–313

    Google Scholar 

  30. Süsskind M, Thürmann PA, Lüke C et al (2012) Adverse drug reactions in a complementary medicine hospital: a prospective, intensified surveillance study. Evid Based Complement Alternat Med 2012:320760. doi:10.1155/2012/320760

  31. Tangiisuran B, Davies JG, Wright JE et al (2012) Adverse drug reactions in a population of hospitalized very elderly patients. Drugs Aging 29(8):669–679

    Google Scholar 

  32. Sikdar KC, Dowden J, Alaghehbandan R et al (2012) Adverse drug reactions in elderly hospitalized patients: a 12-year population-based retrospective cohort study. Ann Pharmacother 46(7-8):960–971

    Google Scholar 

  33. Lobo MG, Pinheiro SM, Castro JG et al (2013) Adverse drug reaction monitoring: support for pharmacovigilance at a tertiary care hospital in Northern Brazil. BMC Pharmacol Toxicol 14:5. doi:10.1186/2050-6511-14-5

  34. Ponte ML, Ragusa M, Armenteros C et al (2013) Importance of pharmacovigilance in current medical practice (abstract, in Spanish). Medicina (B Aires) 73(1):35–38

  35. Camargo AL, Cardoso Ferreira MB et al (2006) Adverse drug reactions: a cohort study in internal medicine units at a university hospital. Eur J Clin Pharmacol 62:143–149

    Google Scholar 

  36. Chien JY, Ho RJ (2011) Drug delivery trends in clinical trials and translational medicine: Evaluation of pharmacokinetic properties in special populations. J Pharm Sci 100:53–58

    Article  PubMed  CAS  Google Scholar 

  37. Demoly P, Bousquet J (2001) Epidemiology of drug allergy. Curr Opin Allergy Clin Immunol 1:305–310

    PubMed  CAS  Google Scholar 

  38. Rawlins MD (2004) NICE work—providing guidance to the British National Health Service. N Engl J Med 351(3):1381–1385

    Google Scholar 

  39. Castro-Pastrana LI, Carleton BC (2011) Improving pediatric drug safety: need for more efficient clinical translation of pharmacovigilance knowledge. J Popul Ther Clin Pharmacol 18:e76–e88

    PubMed  Google Scholar 

  40. Napoleone E (2010) Children and ADRs (Adverse Drug Reactions). Ital J Pediatr 36:4

    Google Scholar 

  41. Impicciatore M (2003) Pharmacogenomic can give children safer medicines. Arch Dis Child 88(4):366

    Article  PubMed  CAS  Google Scholar 

  42. Leeder JS (2003) Developmental and pediatric pharmacogenomics. Pharmacogenomics 4:331–341

    Article  PubMed  CAS  Google Scholar 

  43. Lindell-Osuagwu L, Korhonen MJ, Saano S et al (2009) Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature. J Clin Pharm Ther 34:277–287

    Google Scholar 

  44. Smyth RM, Gargon E, Kirkham J, Cresswell L et al (2012) Adverse drug reactions in children—a systematic review. PLoS One 3:e24061

    Google Scholar 

  45. Buajordet I, Wesenberg F, Brors O (2002) Langslet A Adverse drug events in children during hospitalization and after discharge in a Norwegian University Hospital. Acta Paediatr Int J Paediatr 91:88–94

    Article  CAS  Google Scholar 

  46. Impicciatore P, Choonara I, Clarkson A et al (2001) Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol 52(1):77–83

    Google Scholar 

  47. Weiss J, Krebs S, Hoffmann C et al (2002) Survey of adverse drug reactions on a pediatric ward: A strategy for early and detailed detection. Pediatrics 110:254–257

    Google Scholar 

  48. Easton-Carter KL, Chapman CB, Brien JAE (2003) Adverse drug reactions in paediatrics: Are we getting the full picture? J Pharm Pract Res 33:106–110

    Google Scholar 

  49. Neubert A, Dormann H, Weiss J et al (2004) The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Safety 27:1059–1067

    Google Scholar 

  50. Fattahi F, Pourpak Z, Moin M et al (2005) Adverse drug reactions in hospitalized children in a department of infectious diseases. J Clin Pharmacol 45:1313–1318

    Google Scholar 

  51. Haffner S, von Laue N, Wirth S (2005) Thurmann PADetecting adverse drug reactions on paediatric wards—intensified surveillance versus computerized screening of laboratory values. Drug Safety 28:453–464

    Article  PubMed  Google Scholar 

  52. dos Santos DB, Coelho HL (2006) Adverse drug reactions in hospitalized children in Fortaleza, Brazil. Pharmacoepidemiol. Drug Saf 15:635–640

    Google Scholar 

  53. Jha N, Bajracharya O, Namgyal T (2007) Prevalence of adverse drug reactions with commonly prescribed drugs in different hospitals of Kathmandu valley. Kathmandu Univ M J 5:504–510

    CAS  Google Scholar 

  54. Ganeva M, Gancheva T, Lazarova R et al (2007) A prospective study of adverse drug reactions in a dermatology department. Methods Find Exp Clin Pharmacol 29:107–112

    Google Scholar 

  55. Baniasadi S, Fahimi F (2008) Shalviri G Developing an adverse drug reaction reporting system at a teaching hospital. Basic Clin Pharmacol Toxicol 102:408–411

    Article  PubMed  CAS  Google Scholar 

  56. Farrokhi S, Pourpak Z, Fattahi F et al (2009) Adverse drug and medical instrument reactions in a pediatric intensive care unit. Pharmacoepidemiol Drug Saf 18(8):761–762

    Google Scholar 

  57. Dos Santos L, Martinbiancho JK Silva MM et al (2009) Adverse drug reactions in general pediatrics units of a university hospital. Lat Am J Pharm 28:695–699

    Google Scholar 

  58. Agarwal S, Classen D, Larsen G et al (2010) Prevalence of adverse events in pediatric ICUs in the United States. Pediatr Crit Care Med 11(5):568–578

    Article  PubMed  Google Scholar 

  59. Gallagher RM, Mason JR, Bird KA et al (2012) Adverse drug reactions causing admission to a paediatric hospital. PLoS One 7(12):e50127. doi:10.1371/journal.pone.0050127

  60. Khan LM, Al-Harthi SE, Saadah OI (2013) Adverse drug reactions in hospitalized pediatric patients of Saudi Arabian University Hospital and impact of pharmacovigilance in reporting ADR. Saudi Pharm J 21:261–266

  61. Oehme A-K, Rashed AN, Hefele B et al (2012) Adverse drug reactions in hospitalized children in Germany are decreasing: results of a nine year cohort-based comparison. PLoS One 7(9):e44349

    Google Scholar 

  62. Holbrook AM, Pereira JA, Labiris R et al (2005) Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165(10):1095–1106

    Google Scholar 

  63. Office for National Statistics, England (2012) Cancer Statistics Registrations. Available at: http://www.ons.gov.uk)

  64. Kaushal R, Shojania KG, Bates DW (2003) Effects of computerized physician order entry and clinical decision support systems on medication safety: a systematic review. Arch Intern Med 163:1409–1416

    Article  PubMed  Google Scholar 

  65. Hartwig SC, Siegel J, Schneider PJ (1992) Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 49:2229–2232

    PubMed  CAS  Google Scholar 

  66. Temple ME, Robinson RF, Miller JC et al (2004) Frequency and preventability of adverse drug reactions in pediatric patients. Drug Saf 27:819–829

    Google Scholar 

  67. Bavdekar SB, Karande S (2006) National pharmacovigilance program. Indian Pediatr 43:27–32

    PubMed  Google Scholar 

  68. Oshikoya KA, Njokanma OF, Chukwura HA et al (2007) Adverse drug reactions in Nigerian children. Paediatr Perinat Drug Therapy 8:81–88

    Google Scholar 

  69. Priyadharsini R, Surendiran A, Adithan C et al (2011) A study of adverse drug reactions in pediatric patients. J Pharmacol Pharmacother 2:277–280

    Google Scholar 

  70. Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective studies. JAMA 279:1200–1205

    Article  PubMed  CAS  Google Scholar 

  71. Gurwitz JH, Field TS, Harrold LR et al (2003) Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 289(9):1107–1116

    Article  PubMed  Google Scholar 

  72. Wester K, Jonnson AK, Sigset O et al (2008) Incidence of fatal adverse drug reactions: a population based study. Br J Clin Pharmacol 65:573–579

    Google Scholar 

  73. Tramèr MR, Moore RA, Reynolds DJ et al (2000) Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 85(1–2):169–182

    Google Scholar 

  74. Paessens BJ, von Schilling C, Berger K et al (2011) Health resource consumption and costs attributable to chemotherapy-induced toxicity in German routine hospital care in lymphoproliferative disorder and NSCLC patients. Ann Oncol 22(10):2310–2319. doi:10.1093/annonc/mdq759

    Google Scholar 

  75. Ihbe-Heffinger A, Paessens B, Berger K et al (2013) The impact of chemotherapy-induced side effects on medical care usage and cost in German hospital care - an observational analysis on non-small-cell lung cancer patients. Support Care Cancer 21(6):1665–1675

    Google Scholar 

  76. Niraula S, Seruga B, Ocana A et al (2012) The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol 30(24):3012–3019. doi:10.1200/JCO.2011.40.3824

    Google Scholar 

  77. Seruga B, Sterling L, Wang L et al (2011) Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. J Clin Oncol 29(2):174–185. doi:10.1200/JCO.2010.31.9624

    Google Scholar 

  78. Nebeker JR, Barach P, Samore MH (2004) Clarifying adverse drug events: a clinician’s guide to terminology, documentation, and reporting. Ann Intern Med 140:795–801

    Article  PubMed  Google Scholar 

  79. Aagaard L, Hansen EH (2010) Adverse drug reactions reported for systemic antibacterials in Danish children over a decade. Br J Clin Pharmacol 70:765–768

    Article  PubMed  Google Scholar 

  80. Clavenna A, Bonati M (2009) Adverse drug reactions in childhood: A review of prospective studies and safety alerts. Arch Dis Child 94:724–728

    Article  PubMed  CAS  Google Scholar 

  81. Clavenna A, Bonati M (2009) ADR Epidemiology in Paediatrics. M&B 28:503–504

    Google Scholar 

  82. Schumock GT, Thornton JP (1992) Focusing on the preventability of adverse drug reactions. Hosp Pharm 27:538

    PubMed  CAS  Google Scholar 

  83. Hallas J, Harvald B, Gram LF et al (1990) Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. J Intern Med 228(2):83–90

    Google Scholar 

  84. Imbs JL, Pletan Y, Spriet A (1998) Assessment of preventable iatrogenic drug therapy: Methodology. Round Table No 2 at Giens XIII (in French). Therapie 53(4):365–370

    PubMed  CAS  Google Scholar 

  85. Hakkarainen KM, Hedna K, Petzold M et al (2012) Percentage of patients with preventable adverse drug reactions and preventability of adverse drug reactions—a meta-analysis. PLoS One 7(3):e33236. doi:10.1371/journal.pone.0033236

  86. Kanjanarat P, Winterstein AG, Johns TE et al (2003) Nature of preventable adverse drug events in hospitals: A literature review. Am J Health-Syst Pharm 60:1750–1759

    Google Scholar 

  87. Krahenbuhl-Melcher A, Schlienger R, Lampert M, Haschke M et al (2007) Drug-related problems in hospitals: A review of the recent literature. Drug Saf 30(5):379–407

    Google Scholar 

  88. Passarelli MC, Jacob-Filho W , Figueras A (2005) . Adverse drug reactions in an elderly hospitalised population: inappropriate prescription is a leading cause. Drugs Aging 22(9):767–777

    Google Scholar 

  89. Farcas A, Sinpetrean A, Mogosan C et al (2010) Adverse drug reactions detected by stimulated spontaneous reporting in an internal medicine department in romania. Eur J Intern Med 21(5):453–457. doi:10.1016/j.ejim.2010.05.014

  90. Ahern F, Sahm LJ, Lynch D et al (2013) Determining the frequency and preventability of adverse drug reaction-related admissions to an Irish University Hospital: a cross-sectional study. Emerg Med J [Epub ahead of print]

  91. Pirmohamed M, James S, Meakin S et al (2004) Adverse drug reactions as a cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329:15–19

    Article  PubMed  Google Scholar 

  92. Davies EC, Green CF, Mottram DR et al (2007) Adverse drug reactions in hospitals. Narrat Rev Curr Drug Saf 2:79–87

    Google Scholar 

  93. Rodriguez-Monguio R, Otero MJ, Rovira J (2003) Assessing the economic impact of adverse drug effects. Pharmacoeconomics 21(9):623–650

    Article  PubMed  Google Scholar 

  94. Lundkvist J, Jönsson B (2004) Pharmacoeconomics of adverse drug reactions. Fundam Clin Pharmacol 18:275–280

    Article  PubMed  CAS  Google Scholar 

  95. Bates DW, Spell N, Cullen DJ et al (1997) The costs of adverse drug events in hospitalized patients. JAMA 277:307–311

    Article  PubMed  CAS  Google Scholar 

  96. Egbring M, Far E, Knuth A et al (2011) Performance of different data sources in identifying adverse drug events in hospitalized patients. Eur J Clin Pharmacol 67(9):909–918. doi:10.1007/s00228-011-1020-9

    Google Scholar 

  97. Wu C, Bell CM, Wodchis WP (2012) Incidence and economic burden of adverse drug reactions among elderly patients in Ontario emergency departments: a retrospective study. Drug Saf 35(9):769–781

    PubMed  Google Scholar 

  98. Burgess CL D’Arcy C, Holman J et al (2005) Adverse drug reactions in older Australians, 1981-2002. Med J Aust 182:267–270

    Google Scholar 

  99. U.S. Department of Health and Human Services (1999) Centers for Medicare and Medicaid Services. Expanded modified Medicare provider analysis and review Department of Health and Human Services, Baltimore

    Google Scholar 

  100. Wasserfallen J, Livio F, Buclin T et al (2001) Rate, type, and cost of adverse drug reactions in emergency department admissions. Eur J Intern Med 12:442–444

    Google Scholar 

  101. Routledge PA, O’Mahony MS, Woodhouse KW (2003) Adverse drug reactions in elderly patients. Br J Clin Pharmacol 57:121–126

    Article  Google Scholar 

  102. Trontell A (2004) Expecting the unexpected—drug safety, pharmacovigilance, and the prepared mind. N. Engl. J. Med. 2004; 351, 1385-1387

    Google Scholar 

  103. Topol EJ (2004) Failing the public health: rofecoxib, Merck, and the FDA [editorial]. N Engl J Med 351:1709

    Article  Google Scholar 

  104. Furberg CD, Levin AA, Gross PA et al (2006) The FDA and drug safety. Arch Intern Med 166:1938–1942

    Google Scholar 

  105. Kesselheim AS, Avorn J (2007) The role of litigation in defining drug risks. JAMA 297:308–311

    Article  PubMed  CAS  Google Scholar 

  106. Kuehn BM (2006) IOM: overhaul drug safety monitoring. JAMA 296:2075–2076

    Article  PubMed  CAS  Google Scholar 

  107. Psaty BM, Burke SP (2006) Protecting the health of the public—Institute of Medicine recommendations on drug safety. N Engl J Med 355:1753–1755

    Article  PubMed  CAS  Google Scholar 

  108. Curfman GD, Morrissey S, Drazen JM (2006) Blueprint for a stronger Food and Drug Administration. N Engl J Med 355:1821

    Article  PubMed  CAS  Google Scholar 

  109. Du W, Tutag Lehr V, Lieh-Lai M et al (2012). An algorithm to detect adverse drug reactions in the neonatal intensive care unit: a new approach. J Clin Pharmacol 53:87–95

    Google Scholar 

  110. Classen DC, Resar R, Griffin F et al (2011) 'Global trigger tool' shows that adverse events in hospitals may be ten times greater than previously measured. Health Aff (Millwood) 30(4):581–589. doi:10.1377/hlthaff.2011.0190. Erratum in Health Aff (Millwood). 2011 June; 30(6):1217

  111. Hung SI, Chung WH, Liu ZS et al (2010) Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 11:349–356

    Article  PubMed  CAS  Google Scholar 

  112. Aihara M (2011) Pharmacogenetics of cutaneous adverse drug reactions. J Dermatol 38(3):246–254

    Article  PubMed  CAS  Google Scholar 

  113. Thong BY, Tan TC (2011) Epidemiology and risk factors for drug allergy. Br J Clin Pharmacol 71(5):684–700

    Article  PubMed  Google Scholar 

  114. Daly AK (2010) Pharmacogenetics and human genetic polymorphisms. Biochem J 429:435–449

    Article  PubMed  CAS  Google Scholar 

  115. Daly AK (2012) Using genome-wide association studies to identify genes important in serious adverse drug reactions. Annu Rev Pharmacol Toxicol 52:21–35

    Article  PubMed  CAS  Google Scholar 

  116. Agewall S, Cattaneo M, Collet JP et al (2013). Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J. doi: 0.1093/eurheartj/eht042

  117. Rashid S, Rajan D, Iqbal J et al (2012) Inappropriate use of gastric acid suppression therapy in hospitalized patients with Clostridium difficile—associated diarrhea: a ten-year retrospective analysis. ISRN Gastroenterol 2012:902320. doi:10.5402/2012/902320

Download references

Acknowledgments

The author thanks his mentor Prof. Dr Mansour I. Sulaiman, his colleagues Dr. Sameer E. Al-Harthi and Dr. Ahmed A. Shaker, Department of Pharmacology, Faculty of Medicine, King Abdulaziz University, for their excellent advice that culminated in this article.

Disclosure

None.

Author information

Authors and Affiliations

  1. Department of Pharmacology, Faculty of Medicine, King Abdulaziz University, P.O. Box 80205, Jeddah, 21589, Saudi Arabia

    Lateef Mohiuddin Khan

Authors
  1. Lateef Mohiuddin Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lateef Mohiuddin Khan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Khan, L.M. Comparative epidemiology of hospital-acquired adverse drug reactions in adults and children and their impact on cost and hospital stay – a systematic review. Eur J Clin Pharmacol 69, 1985–1996 (2013). https://doi.org/10.1007/s00228-013-1563-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-013-1563-z

Keywords

Search

Navigation